CareFusion soars in Q4; Accuray seeks $75M as sales drop;

 @FierceMedDev: Ultrasound elastography eyed as cancer Dx method. Report | Follow @FierceMedDev

 @MarkHFierce: India is competing with the larger device companies by launching firms that make cheaper, quality alternatives. News | Follow @MarkHFierce

 @DamianFierce: LabCorp joins the list of diagnostics providers expecting Medicare cuts to take a bite out of 2013 revenue. Story | Follow @DamianFierce

> CareFusion ($CFN) saw its net income soar 14% last quarter, bringing in $192 million on $909 million in sales. Story

> Accuray ($ARAY) is seeking to raise $75 million in debt financing as its sales plummet and debts mount. News

> Covidien ($COV) posted strong two-year safety and efficacy results for its Solitaire FR revascularization device, designed to remove blood clots in patients suffering from strokes. More

> Invacare ($IVC), working to put itself back together after a damaging FDA consent decree, is planning $100 million in cuts to get back to profitability in 2013. Release

> St. Jude Medical ($STJ) released more data on its Amplatzer PFO Occluder, finding that patients treated with the tiny device had fewer, smaller strokes that were less likely to originate from blood clots passing through the patent foramen ovale, an opening in the heart. Item

> California's EndoSee has raised $1.6 million of a $2.5 million round to develop a device that would allow in-office uterine cavity examination. Article

Biotech News

 @FierceBiotech: Pfizer to lop off Asian research unit amid major R&D downsizing. Story | Follow @FierceBiotech

@RyanMFierce: Troubled biotech Tranzyme mulls potential sale after R&D face plants. More | Follow @RyanMFierce

> French biotech rapidly stuck on losing side of hep C revolution. News

> A new wave of biotechs takes shape in the U.K. Editor's Corner

> Oncolytics Biotech surges on lung cancer data. Story

Pharma News

@FiercePharma: Turns out, Vivus' slow launch of Qsymia may be best plan. News | Follow @FiercePharma

@EricPFierce: Sun tells Taro shareholders to forget it, cancels $685 million offer for Israeli generic drug player. Report | Follow @EricPFierce

@AlisonBFierce: Evidence of a link between GSK's Pandemrix and a spike in narcolepsy cases is putting AS03 under intense scrutiny. More | Follow @AlisonBFierce

> Court spoons out good news for Merck investors. Report

> Pfizer cuts some more, closing R&D site in Singapore. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.